EDMONTON, July 10 /CNW/ - QSV Biologics, Ltd (QSV), a North American based biologics CMO located in Edmonton, Canada, and Alseres Pharmaceuticals, Inc., (Alseres) a publicly traded (Nasdaq: ALSE - News) Central Nervous System diagnosis and treatment company located in Hopkinton, Massachusetts, U.S.A., announced today the signing of a contract for the process development and cGMP manufacturing of Cethrin(R) for spinal cord injury. QSV will be responsible for technology transfer, process development and cGMP manufacture of phase IIb/III clinical trial material in their commercially licensed cGMP manufacturing facility. Cethrin(R), licensed by Alseres from BioAxone Therapeutics, is a Rho inhibitor that stimulates axon regeneration.
